US 11,732,256 B2
Multivalent glycopeptides that tightly bind to target proteins
Isaac J. Krauss, Waltham, MA (US); and Satoru Horiya, Waltham, MA (US)
Assigned to BRANDEIS UNIVERSITY, Waltham, MA (US)
Filed by Brandeis University, Waltham, MA (US)
Filed on Jan. 13, 2020, as Appl. No. 16/740,750.
Application 16/740,750 is a continuation of application No. 15/101,221, granted, now 10,563,193, previously published as PCT/US2014/068195, filed on Dec. 2, 2014.
Claims priority of provisional application 61/910,710, filed on Dec. 2, 2013.
Prior Publication US 2020/0140853 A1, May 7, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C12N 15/10 (2006.01); G01N 33/68 (2006.01); C07K 19/00 (2006.01); A61K 39/21 (2006.01); C07K 16/10 (2006.01)
CPC C12N 15/1058 (2013.01) [A61K 39/21 (2013.01); C07K 16/1063 (2013.01); C07K 19/00 (2013.01); C12N 15/1062 (2013.01); G01N 33/6845 (2013.01); A61K 2039/575 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/91 (2013.01); C12N 2740/16122 (2013.01); C12N 2740/16134 (2013.01); G01N 2405/00 (2013.01)] 9 Claims
 
1. A method of inducing an immune response in an individual comprising:
administering to an individual: (i) a glycopolypeptide comprising one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopolypeptide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM; (ii) an immunogenic conjugate comprising said glycopolypeptide covalently or non-covalently bound to an immunogenic carrier molecule; or (iii) a pharmaceutical composition comprising a pharmaceutically acceptable carrier and said glycopolypeptide or said immunogenic conjugate,
wherein said administering is effective to induce an immune response against the glycopolypeptide, and
wherein the glycopolypeptide comprises (a) the amino acid sequence of XxSIPxYTY (SEQ ID NO: 2) where each x at positions 2 and 6 is optional and can be any amino acid and X at position 1 is one of said one or more modified amino acid residues, or (b) one of the following amino acid sequences:
 
Sequence SEQ ID NO:
 
XHPYNTSRTSAXXAALKXQVTDXYALALFHRIL 13
 
XSPHLPVLLCKXVLNDGRRIVQXSCELPXVRRS 14
 
XLXFIRIYPTRXQYVYHAPLLTXVRXSPTGPLI 15
 
XCYVTVIPAXNXPEARLGIVCHXPGIRRGKALY 16
 
XSPHLPVLLSKXVLNDGRRIVQXSSELPXVRRS 52
 
XXAALKXQVTDXYALALFHRIL 56
 
where X is one of said one or more modified amino acid residues.